Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

NCT07506876 is registered in ClinicalTrials.gov with Legacy Health System as lead sponsor.

NCT NCT07506876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07506876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
Lead sponsor
Legacy Health System
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2026
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer - infiltrating ductal carcinoma, her-2 positive breast cancer